Rituxan Hycela (rituximab and hyaluronidase human) Patient Assistance Program
Don’t let the high cost of brand subcutaneous rituximab disrupt your lymphoma or chronic lymphocytic leukemia treatment. We help eligible patients access Rituxan Hycela (rituximab and hyaluronidase human SC) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Rituxan Hycela (rituximab and hyaluronidase human) is FDA-approved for follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL) — same rituximab as IV Rituxan, formulated with recombinant hyaluronidase for SC injection over 5–7 minutes (vs 3–4 hour IV infusion). Same clinical efficacy as IV rituximab.
- Without assistance, Rituxan Hycela costs commonly run approximately $9,000–$14,000 per injection.
- Through AffordMyPrescriptions, qualifying patients can access Rituxan Hycela for a flat $69.95 per month.
- Rituximab biosimilars now widely available (IV — significantly cheaper): Ruxience, Truxima, Riabni. Rituxan Hycela is uniquely SC. Other CD20-directed therapies: obinutuzumab (Gazyva — IV), ofatumumab (Arzerra IV; Kesimpta SC for MS). B-cell malignancy therapy: rituximab-based regimens (R-CHOP, R-CVP, BR, RB/RBV for CLL); newer targeted: acalabrutinib/zanubrutinib BTK inhibitors, venetoclax BCL-2 inhibitor, CAR-T therapies (Yescarta, Kymriah, Breyanzi). Comprehensive lymphoma testing.
What is Rituxan Hycela Prescription Assistance Program?
The Rituxan Hycela Patient Assistance Program helps eligible patients access this SC rituximab at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Rituxan Hycela PAP enrollment for a flat $69.95 per month — so you never face a gap in Rituxan Hycela lymphoma or CLL therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Rituxan Hycela enrollment — so you never face a gap in your B-cell malignancy treatment.
Pharmacy Price Comparison
- Without assistance, Rituxan Hycela costs thousands per injection. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic chemotherapy (partial) | varies | Regimen-dependent |
| Cancer center pharmacy | ~$14,000/dose | Save substantially |
| Community oncology | ~$13,000/dose | Save substantially |
| Hospital outpatient | ~$12,000/dose | Save substantially |
| 340B-eligible institution | ~$9,000/dose | Save substantially |
| Rituximab biosimilar (IV alt) | ~$3,500/dose | IV biosimilar much cheaper |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Rituxan Hycela — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Rituxan Hycela Prescription Program?
The Rituxan Hycela Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Rituximab biosimilars (IV) offer major cost savings if SC formulation isn’t essential. Rituxan Hycela’s 5–7 minute SC injection vs 3–4 hour IV infusion is a substantial time and comfort advantage.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Rituxan Hycela assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Rituxan Hycela is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Rituxan Hycela:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $9,000–$14,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Rituxan Hycela assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Rituxan Hycela Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Rituxan Hycela:
Rituxan Hycela is subcutaneous rituximab formulated with recombinant hyaluronidase — enables SC injection over 5–7 minutes instead of 3–4 hour IV infusion. Same rituximab. Same efficacy. Dramatically reduced chair time for CD20-directed therapy.
How It Works:
CD20 is a cell surface protein expressed on B-cells and B-cell malignancies (follicular lymphoma, DLBCL, CLL, other B-cell lymphomas). Rituximab was the first monoclonal antibody approved for cancer — revolutionized B-cell malignancy treatment. Standard-of-care component of most B-cell lymphoma regimens (R-CHOP, R-CVP, BR, RB/RBV for CLL) and CLL therapy. Rituximab binds CD20 on B-cells — mediates antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. Depletes B-cells. Hyaluronidase in Rituxan Hycela transiently digests extracellular matrix hyaluronan, allowing large-volume SC injection with rapid absorption — equivalent PK/PD to IV administration. Rituximab biosimilars (IV) offer same mechanism at lower cost.
Form and Use:
Rituxan Hycela SC injection in abdomen. Fixed dose over 5–7 minutes. Requires initial IV rituximab dose for safety monitoring before switching to SC. Given at cancer center or oncology clinic.
Generic Availability:
No generic Rituxan Hycela. Rituximab biosimilars (all IV): Ruxience, Truxima, Riabni — biosimilars to Rituxan with equivalent efficacy at significantly lower cost. Rituxan Hycela uniquely offers SC formulation. Other CD20-directed therapies: obinutuzumab (Gazyva — IV; used in CLL 1L and follicular lymphoma; more potent than rituximab), ofatumumab (Arzerra IV for CLL; Kesimpta SC for multiple sclerosis). B-cell malignancy therapy: rituximab-based regimens (R-CHOP for DLBCL, R-CVP, BR for follicular, RB/RBV for CLL); BTK inhibitors (acalabrutinib, zanubrutinib); venetoclax (Venclexta) BCL-2 inhibitor; CAR-T therapies (Yescarta, Kymriah, Breyanzi) for relapsed DLBCL; bispecific antibodies (Columvi glofitamab, Lunsumio mosunetuzumab, Epkinly epcoritamab). LLS resources.
Warnings:
Infusion reactions (typically first infusion — SC form usually less severe than IV), tumor lysis syndrome (high tumor burden — monitor and prophylax), severe skin reactions (SJS/TEN, others), progressive multifocal leukoencephalopathy (PML — rare but serious opportunistic viral infection), hepatitis B reactivation (BOXED WARNING — screen HBV before starting; monitor for reactivation; treat with antivirals if positive; can cause fulminant hepatitis and death), cytopenias (neutropenia, thrombocytopenia — monitor), immune deficiency and infections (B-cell depletion — vaccinate before starting), embryo-fetal considerations. Other: fatigue, headache, nausea, fever. Oncology follow-up essential.
FAQ (Frequently Asked Questions)
How much does Rituxan Hycela cost without insurance?
$9,000–$14,000 per SC injection at cancer centers. Rituximab biosimilars (IV) are significantly cheaper ($3,000–$5,000/dose) — Ruxience, Truxima, Riabni. Advantage of Rituxan Hycela is SC administration convenience.
How is Rituxan Hycela different from IV Rituxan?
Same rituximab molecule. SC formulation with recombinant hyaluronidase enables injection over 5–7 minutes instead of 3–4 hour IV infusion. Same efficacy and safety. Major advantage: dramatically reduced chair time. First IV dose required for safety monitoring before switching to SC.
How does Rituxan Hycela compare to rituximab biosimilars?
Rituximab biosimilars (Ruxience, Truxima, Riabni) are IV formulations biosimilar to Rituxan — significantly cheaper. Rituxan Hycela’s advantage is SC administration convenience. Choose based on cost, convenience preference, and insurance coverage. Same clinical efficacy for B-cell malignancies.
What B-cell malignancies is Rituxan Hycela approved for?
Follicular lymphoma (in combination and as maintenance), diffuse large B-cell lymphoma (in combination — R-CHOP), and chronic lymphocytic leukemia (in combination). Newer B-cell targeted therapies (BTK inhibitors, venetoclax, CAR-T, bispecifics) provide additional options.
Do I need hepatitis B testing before Rituxan Hycela?
Yes — hepatitis B reactivation is a boxed warning. HBV screening essential before starting. Patients with prior HBV need antiviral prophylaxis to prevent reactivation which can be fulminant. Discuss with your oncology team.
Take Control of Your Medication Costs
Rituximab revolutionized B-cell malignancy treatment — SC convenience is a meaningful patient benefit. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.